Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

U.S. development Phase success rates for rare and common disease drugs 2006-2015

Probability of success for new rare disease and high prevalence disease drugs in the U.S. by development phase from 2006 to 2015

by Statista Research Department, last edited May 25, 2016
U.S. development Phase success rates for rare and common disease drugs 2006-2015 This statistic shows the probability of success for new rare disease and high prevalence disease drugs in the U.S. through the various stages of development, from January 1, 2006 to December 31, 2015. It was found that while the probability that a new drug for a chronic high prevalence disease makes it from Phase I to approval was only 8.7 percent, it was 25.3 percent for rare disease drugs.
Show more

Probability of success for new rare disease and high prevalence disease drugs in the U.S. by development phase from 2006 to 2015

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Related Studies: Available to Download in PDF or PPTX Format
Orphan drugs
Orphan drugs

All Information
in one Presentation

Orphan drugs

Everything On "Orphan drugs" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield

Marlene Greenfield
Vice President, Hearst Magazines

Statistics on "Orphan drugs"
  • Market overview
  • Companies
  • Products
  • Research and development
  • Rare diseases
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: You might find this interesting as well
Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.